$6.79 0.00%
BVS Stock Price vs. AI Score
Data gathered: October 7

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Bioventus (BVS)

Analysis generated October 6, 2025. Powered by Chat GPT.

Bioventus Inc. is a company focused on enhancing active healing. They develop and market clinically proven, cost-effective solutions that help people heal quickly and safely. Bioventus products are known for their focus on biologics, trauma, joint preservation, as well as surgical solutions. Their primary commitment is to patient wellness through advanced technologies and innovative therapies.

Read full AI stock Analysis

Stock Alerts - Bioventus (BVS)

company logo Bioventus | September 26
Price is down by -6.5% in the last 24h.
company logo Bioventus | August 22
Price is up by 8.1% in the last 24h.
company logo Bioventus | August 6
Price is up by 8.5% in the last 24h.
company logo Bioventus | August 5
Price is down by -7.8% in the last 24h.

Download our app to get future alerts delivered in real-time.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body’s natural healing process in the United States and internationally.


Bioventus
Price $6.79
Target Price Sign up
Volume 231,210
Market Cap $470M
Year Range $6.14 - $11.05
Dividend Yield 0%
PE Ratio 234
Analyst Rating 67% buy
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '25148M46M102M7.5M30M0.210
Q1 '25124M41M83M-2.6M16M-0.040
Q4 '24154M51M103M-160,00022M0.150
Q3 '24139M45M94M-4.8M17M0.060
Q2 '24151M48M104M-24M-16M0.190

Insider Transactions View All

CHURCH KATRINA J filed to sell 55,557 shares at $7.6.
April 15 '25
D'Adamio Anthony filed to sell 131,416 shares at $7.6.
April 15 '25
Singleton Mark Leonard filed to sell 141,088 shares at $7.6.
April 15 '25
Singleton Mark Leonard filed to sell 131,963 shares at $9.8.
March 25 '25
D'Adamio Anthony filed to sell 124,449 shares at $9.8.
March 18 '25

What is the Market Cap of Bioventus?

The Market Cap of Bioventus is $470M.

What is Bioventus' PE Ratio?

As of today, Bioventus' PE (Price to Earnings) ratio is 234.

What is the current stock price of Bioventus?

Currently, the price of one share of Bioventus stock is $6.79.

How can I analyze the BVS stock price chart for investment decisions?

The BVS stock price chart above provides a comprehensive visual representation of Bioventus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bioventus shares. Our platform offers an up-to-date BVS stock price chart, along with technical data analysis and alternative data insights.

Does BVS offer dividends to its shareholders?

As of our latest update, Bioventus (BVS) does not offer dividends to its shareholders. Investors interested in Bioventus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Bioventus?

Some of the similar stocks of Bioventus are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Top Stocks
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
You need to log in to use AltIndex AI Chat.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.